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RatsAbstract The present study was undertaken to assess the effect of erythropoietin (EPO) and/or
spirulina to treat alloxanized-diabetic rats. Eighty male albino rats were equally divided into eight
groups; Group I: Normal control rats, Group II: Non-diabetic rats treated with EPO (40 U/kg)
injected subcutaneously three times weekly for 3 weeks, Group III: Non-diabetic rats administered
orally with spirulina (2 g/kg/d) for 21 days, Group IV: Non-diabetic rats treated by EPO (40 U/kg)
together with spirulina (2 g/kg/d) as mentioned in groups II & III, Group V: Alloxanized-diabetic
rats. Group VI: Diabetic rats treated with EPO (40 U/kg) as in group II, Group VII: Diabetic rats
administered with spirulina (2 g/kg/d) as in group III, Group VIII: Diabetic rats were given with
EPO (40 U/kg) and spirulina (2 g/kg/d) as in group IV. Diabetic rat group showed a signiﬁcant
increase in glucose and NO; and a signiﬁcant decrease in insulin, SOD and CAT levels. Diabetic
rats treated with EPO or/and spirulina recorded a signiﬁcant decrease in the glucose and NO levels;
and a signiﬁcant increase in insulin, SOD and CAT levels when compared with the diabetic group.
Histopathologically, diabetic rats treated with EPO or spirulina showed a slight improvement of
pancreatic islets and acinar cells, diabetic rats treated with EPO & spirulina together showed an
obvious recovery to approximately normal status. IHC, the expression of insulin producing cells
(b-cells) of diabetic rats was improved in the three treatment groups with a lesser afﬁnity for
EPO than spirulina while with both together showed marked recovery into normal status. In con-
clusion, all the changes were minimized in spirulina administered group more than EPO group,
however, the co-treatment of EPO and spirulina exerted stronger anti-hyperglycemic effects than
treatment with each agent alone.
ª 2015 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Diabetes mellitus is a universal metabolic disorder character-
ized by hyperglycemia, hyperlipidemia, hyperaminoacidemia
Improvement in beta-islets of Langerhans in alloxan-induced diabetic rats 21and hypoinsulinemia that leads to reduction in both insulin
secretion and insulin action (Altan, 2003). There is always a
greater risk of all manifestations of atherosclerosis along with
diabetes mellitus (Khuwaja et al., 2004), as well as association
with a reduced quality of life and increase in risk factors of
mortality and morbidity (Shaw et al., 2009). Type 2 diabetes
mellitus is a chronic disorder of insulin insufﬁciency resulting
in the dysregulation of glucose homeostasis, hyperglycemia
and vascular complications. Diabetes has distinct pathogenic
insufﬁcient functional pancreatic b-cell mass that is required
to maintain euglycemia (Kahn, 2003; Rhodes, 2005). Thus,
one of the overarching goals in the treatment of diabetes is
the preservation and growth of b-cells.
Erythropoietin (EPO), is a glycoprotein hormone with a
molecular mass of 30.4 kD that controls erythropoiesis, it is
produced by interstitial ﬁbroblasts in the kidney in close
association with peritubular capillary and tubular epithelial
cells (Obara et al., 2008). It is also produced in
perisinusoidal cells in the liver. While liver production pre-
dominates in the fetal and perinatal period, renal produc-
tion is predominant during adulthood. EPO is the
hormone that regulates red blood cell production. It also
has other known biological functions (Hand and Brines,
2011; McGee et al., 2012). For example, it plays an impor-
tant role in the brain’s response to neuronal injury (Siren
et al., 2001). EPO is also involved in the wound healing
process (Haroon et al., 2003).
Recent studies have shown that the EPO protects against
diabetes through direct effects on pancreatic cells. The EPO
receptor (EPO-R) is present in nonerythroid tissues, including
the pancreatic islets of human and rodents (Fenjves et al.,
2003; Choi et al., 2010). In particular, several studies have
shown the efﬁcacy of EPO in providing cytoprotection in
experimental models of tissue injury (Brines and Cerami,
2006).
EPO overexpression in human pancreatic islets has been
shown to prevent cytokine-induced cell death (Fenjves et al.,
2004). EPO deﬁciency and a higher incidence of anemia have
been shown in individuals with diabetes, suggesting potential
beneﬁcial effects of EPO in the setting of diabetes (McGill
and Bell, 2006; Thomas, 2006). EPO clinical trial for non-dia-
betic individuals with chronic renal failure was associated with
a signiﬁcant increase in the incidence of hypoglycemia which
raises the intriguing possibility of a direct effect of EPO on
pancreatic b-cells (Dru¨eke et al., 2006).
EPO-R belongs to the cytokine class I receptor superfamily
and utilizes a similar signal transduction pathway as the recep-
tors for growth hormone and prolactin, knockouts of these
show defects in b-cell mass and function (Freemark et al.,
2002; Liu et al., 2004). Collectively, these data raise the
possibility that EPO signaling may have signiﬁcant biological
effects on b-cells and thus may be relevant to diabetes
(Brines and Cerami, 2006; Choi et al., 2010).
Spirulina, refers to the dried biomass of the cyanobac-
terium, Arthrospira platensis, and is a whole product of bio-
logical origin. Spirulina is a name used to describe mainly
two species of Cyanobacteria, A. platensis and Arthrospira
maxima that are commonly used as food and as dietary supple-
ment (Mu¨hling et al., 2006). The number of research articles
discussing the beneﬁcial effects of spirulina is increasing every
year. Spirulina is rich in proteins, carbohydrates,polyunsaturated fatty acids, sterols and some more vital ele-
ments such as calcium, iron, zinc, magnesium, manganese
and selenium. It is a natural source of vitamin B12, vitamin
E, ascorbic acid, tocopherols and a whole spectrum of natural
mixed carotene and xanthophylls phytopigments.
Some of the early health effects of spirulina were in its role
in diabetes management and its signiﬁcant plasma triglycerides
reduction effects (total- and LDL-cholesterol), blood pressure
lowering, improving the antioxidant status, as well as inﬂam-
matory effects (Eun et al., 2008). Recent reports note the
importance of spirulina for its immunomodulatory, anti fati-
gue, radio protective and antioxidant effects particularly on
the biochemical parameters such as SOD and CAT levels
(Mendiola et al., 2010). Spirulina protects against diabetes
through direct effects on pancreatic b-cells (Khursheed et al.,
2012). Recent studies have shown an insulin-like protein
extracted from spirulina to have the same molecular mass,
immunoreactivity and retention time, detected by reversed-
phase chromatography (RP-HPLC), to be similar to that of
the bovine insulin (Anwer et al., 2012).
The present study aimed to assess the impact of treatment
with erythropoietin and the natural extract of the marine algae
(spirulina) separately or in combination on the physiological
and histopathological parameters of experimentally-induced
diabetes in rats.
Materials and methods
Animals and housing conditions
Eighty male albino rats (Rattus rattus) weighing 150 ± 5 g
were used in the current study. They were obtained from the
Breeding Unit of the Egyptian Organization for Vaccine and
Biological Preparation, Cairo, Egypt. All rats were kept under
the same environmental conditions for 2 weeks before the
study. The animals were fed ad Libitum with a standard pellet
diet and allowed free access of water and they were housed in
metal cages in a well-ventilated animal room. All protocols
and procedures adopted for the present investigation were in
accordance with the approval of the Institutional Animal
Ethics Committee of National Research Center and in accor-
dance with recommendation of the proper care and use of lab-
oratory animals.
Induction of diabetes mellitus in rats
The diabetes was induced in the animals by three intraperi-
toneal (i.p.) injections of alloxan monohydrate (Sigma
Aldrich, USA) dissolved in acetate buffered-saline (Merck).
The 1st dose was at a dose of 150 mg/kg as recommended by
Bromme et al. (2000). The 2nd dose was at a 100 mg/kg of
alloxan after 2 days. Finally, the 3rd dose of alloxan
(100 mg/kg) was applied 5 days after the 2nd one. Note, the
2nd and 3rd injections were used to ensure the insult of dia-
betes through the experimental duration.
The rats were fasted overnight, collection of blood samples
and sera glucose determination were drawn from their tail tips.
Sera glucose estimation was done by one touch electronic gly-
cometer using glucose test strips, and the glucose level more
than 250 mg/dl was used in the present study.
22 N.I. El-Desouki et al.EPO and spirulina treatment
EPO in the form of EPREX, (rHuEPO, Epoetin alfa) was
obtained from (Sigma Aldrich, USA). Rats were injected
subcutaneously (s.c.) with EPO (40 U/kg bw), three times
weekly on alternating days for 3 weeks. Spirulina
(International University for Vital Energy I.U.V.E,
Egypt(was given to rats daily by intragastroluminal gavage
at a dose of 2 g/kg/d for 21 days.
Experimental design
Eighty male rats were equally divided into eight groups as
follows:
Group I: Non diabetic normal control rats daily injected
with 0.1 ml saline solution.
Group II: Non-diabetic rats treated s.c. with EPO
(40 U/kg bw) three times weekly on alternating days, for
3 weeks.
Groups III: Non-diabetic rats administered orally with
2 g/kg/d spirulina for 21 days.
Groups IV: Non-diabetic rats given EPO (40 U/kg bw) and
spirulina (2 g/kg/d) as mentioned in groups II & III.
Group V: Alloxanized-diabetic rats.
Group VI: Diabetic rats treated with EPO (40 U/kg bw)
three times weekly on alternating days, for 3 weeks.
Group VII: Diabetic rats administered with 2 g/kg/d spir-
ulina for 21 days.
Group VIII: Diabetic rats co-treated with EPO
(40 U/kg bw) and spirulina (2 g/kg/d) as mentioned in groups
II & III.
At the end of experiment, rats were fasted for 10 h and then
killed under mild (diethyl ether) anesthesia by decapitation.
Blood was collected by cardiac puncture and immediately ana-
lyzed. Blood was collected in two different tubes, i.e. one with
anticoagulant, potassium oxalate and sodium ﬂuoride for
plasma and the other without anticoagulant for serum sep-
aration. Plasma and sera were separated by centrifugation.
For clinical chemistry parameters, blood samples were kept at
room temperature for 1 h, the plasmawas taken for biochemical
assays. A part of pancreatic tissues were stored at 22 C until
analyzed and the others were immediately ﬁxed in 10% neutral
formalin for histological and immunohistochemical studies.
Biochemical parameters
Biochemical parameters were measured using standard kits.
Insulin was determined by the ALPCO. Rat Insulin ELISA
is designed for the quantitative determination of insulin in
rat sera and plasma (Finlay and Dillard, 2007), SOD
EnzyChrom Superoxide Dismutase Assay Kit was used for
SOD (Kuthan, 1986) NO QuantiChrom Nitric Oxide
Assay Kit was used for NO (Ghigo, 2006), CAT Oxi Select
Catalase Activity Assay Kit was used for CAT (Ames et al.,
1993). Blood glucose estimation was done by one touch elec-
tronic glycometer using glucose test strips.
Histological and immunohistochemical (IHC) studies
For histological studies, pieces of pancreas were ﬁxed in 10%
neutral formalin, they were dehydrated through alcohols,cleared in xylene and then embedded in parafﬁn. Parafﬁn sec-
tions were cut at 5 lm thick and were stained with hematoxylin
and eosin ‘‘H&E’’ (Bancroft and Gamble, 2002) for histologi-
cal observation.
IHC detection of pancreatic tissues with immunolocaliza-
tion technique for anti-insulin monoclonal antibody was
performed as previously described (Hsu et al., 1981). IHC reac-
tion was carried out by using avidin biotin peroxidase method
byNovaCastra Laboratories Ltd, UK. Endogenous peroxidase
activity was inhibited by incubation with 0.3% H2O2 for
30 min. The sections were blocked with normal goat serum
for 1 h to prevent non-speciﬁc binding followed by incubation
with the primary insulin monoclonal antibody for 1 h at room
temperature. The sections were incubated with the secondary
antibody (biotinylated anti-mouse IgM) for 30 min. The sec-
tions were then incubated with ExtrAvidin (Sigma) for 45 min
at 37 C. Staining was visualized using diaminobenzidine
(DAB, Sigma), then slides were washed and counterstained with
hematoxylin, cleared, mounted and examined by light micro-
scopy. Finally, the insulin secreting b-cells cytoplasmic sites of
reaction were stained brown and nuclei stained blue.Statistical analysis
Data were fed to the computer and analyzed using IBM
SPSS software package version 20.0, USA. Data were ana-
lyzed using numbers and percentages ± S.D or S.E. For nor-
mally distributed data, comparisons between the eight
studied groups were analyzed using F-test (ANOVA) and
Post Hoc test (LSD). Signiﬁcance was obtained at P< 0.05
or P< 0.01 or p 6 0.001 levels.Results
Physiological and biochemical observations
Effect of EPO or/and spirulina on glucose levels
As shown in Table 1, the data revealed that the treatment of rat
regimes of EPO, spirulina or both together did not affect the
plasma glucose levels as compared to the normal non-treated
rats in group (1). On the other hand, a signiﬁcant increase in
the plasma glucose levels in alloxanized-diabetic rats (groups
5–8) was found comparable to the data from the non-diabetic
rat groups (1–4). Treatment with EPO or spirulina or both
together (groups 6–8) respectively to diabetic rats has signiﬁ-
cantly reduced the plasma glucose levels, particularly in group
(8) which had a reduced glucose levels close to normal values.
Effect of EPO or/and spirulina on plasma insulin levels
Data represented in Table 2 showed that treatment of rats with
EPO, spirulina or both in groups (2–4) respectively have sig-
niﬁcantly increased the plasma insulin levels as compared to
normal controls in group (1). On the other hand, the non-trea-
ted diabetic rats in group (5) showed a signiﬁcant decrease in
the insulin levels as compared to the normal rats in group
(1). Treatment of diabetic rats with EPO, spirulina or co-treat-
ment (groups 6–8) respectively has exerted a signiﬁcant
increase in the plasma insulin levels as compared to control
diabetic rats in group (5). The co-treatment with EPO and spir-
ulina in group (8) exerted the most profound effect (Table 2).
Table 1 Effect of EPO, spirulina or both on plasma glucose levels (mg/dl).
Cases Normal (G1) Non-diabetic +
EPO (G2)
Non-diabetic +
spirulina (G3)
Non-diabetic EPO +
spirulina G4)
Control
diabetic (G5)
Diabetic + EPO (G6) Diabetic + spirulina (G7) Diabetic EPO+ spirulina (G8)
Mean ± SD. 92.4 ± 1.7 90.7 ± 0.9 90.4 ± 0.7 90.1 ± 1.2 257.9a** ± 3.6 231.7a**b** ± 6.4 222.5a**b** ± 6.8 110.7a**b** ± 7.5
a Signiﬁcant vs. normal control group.
b Signiﬁcant vs. control diabetic group.
** Signiﬁcant at P< 0.01.
Table 2 Effect of EPO or spirulina or both together on plasma insulin levels (l/ml).
Cases Normal (G1) Non-diabetic +
EPO (G2)
Non-diabetic +
spirulina (G3)
Non-diabetic EPO+
spirulina (G4)
Control
diabetic (G5)
Diabetic + EPO (G6) Diabetic + spirulina (G7) Diabetic EPO+ spirulina (G8)
Mean ± SD. 14.88 ± 49 15.73a* ± 0.75 16.24 a** ± 0.65 16.48 a** ± 0.42 4.84 a** ± 0.28 6.61 a**b** ± 0.44 6.78 a**b** ± 0.13 14.19 a*b** ± 1.31
a Signiﬁcant vs. normal control group.
b Signiﬁcant vs. control diabetic group.
* Signiﬁcant at P< 0.05.
** Signiﬁcant at P< 0.01.
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Table 3 Effect of EPO or/and spirulina on plasma SOD levels (U/mg).
Cases Normal (G1) Non-diabetic +
EPO (G2)
Non-diabetic +
spirulina (G3)
Non-diabetic EPO+
spirulina (G4)
Control
diabetic (G5)
Diabetic + EPO (G6) Diabetic + spirulina (G7) Diabetic EPO + spirulina (G8)
Mean ± SD. 6.37 ± 0.39 6.54a* ± 0.33 6.81a*** ± 0.44 7.91a*** ± 0.32 2.75a*** ± 0.49 4.35a***b*** ± 0.37 5.46a***b*** ± 0.41 5.85a**b*** ± 0.39
a Signiﬁcant vs. normal control group.
b Signiﬁcant vs. control diabetic group.
* Signiﬁcant at P< 0.05.
** Signiﬁcant at P< 0.01.
*** Signiﬁcantly at p< 0.001.
Table 4 Effect of EPO or/and Spirulina on Plasma CAT Levels (nmol H2O2/s per g).
Cases Normal (G1) Non-diabetic +
EPO (G2)
Non-diabetic +
spirulina (G3)
Non-diabetic EPO +
spirulina (G4)
Control
diabetic (G5)
Diabetic + EPO (G6) Diabetic + spirulina (G7) Diabetic EPO+ spirulina (G8)
Mean ± SD. 12.10 ± 0.32 12.89a*** ± 0.52 14.06a*** ± 0.25 15.16a*** ± 0.27 4.36a*** ± 0.42 6.30a***b*** ± 0.42 8.44a***b*** ± 0.46 10.22a***b*** ± 0.53
a Signiﬁcant vs. normal control group.
b Signiﬁcant vs. control diabetic group.
*** Signiﬁcantly at p< 0.001.
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As shown in Table 3, treatment of the non-diabetic rats in
groups (2–4) respectively with EPO or/and spirulina have sig-
niﬁcantly increased the plasma SOD levels as compared to the
normal control rats in group (1), with the levels in group (4) to
be the highest. Moreover, all diabetic rats in groups (5–8) had
signiﬁcant lower plasma SOD levels as compared to the non-
diabetic rats in groups (1–4). On the other hand, treatment
of the diabetic rats in groups (6–8) with EPO or spirulina or
together respectively, have signiﬁcantly elevated the plasma
SOD levels, particularly in group (8), as compared to the con-
trol diabetic rats in group (5).
Effect of EPO or/and spirulina on plasma CAT levels
Data in Table 4 showed that treatment of the non-diabetic rats
in groups (2–4) respectively with EPO or/and spirulina have
signiﬁcantly increased the plasma CAT levels as compared to
the normal control rats in group (1), with the levels in group
(4) to be the highest. Moreover, all diabetic rats in groups
(5–8) had a signiﬁcant lower plasma CAT levels as compared
to the non-diabetic rats in groups (1–4). The treatment of
the diabetic rats in groups (6–8) with EPO or spirulina or both
respectively, have signiﬁcantly elevated the plasma CAT levels,
particularly in group (8), as compared to the control diabetic
rats in group (5).
Effect of EPO or/and spirulina on plasma NO levels
Data in Table 5 showed that treatment of the non-diabetic rats
in groups (2–4) respectively with EPO or spirulina or both
have signiﬁcantly decreased the plasma NO levels as compared
to the normal control rats in group (1), with the levels in group
(4) to be the lowest. Moreover, all diabetic rats in groups (5–8)
had signiﬁcant higher plasma NO levels as compared to the
non-diabetic rats in groups (1–4). On the other hand, treat-
ment of the diabetic rats in groups (6–8) with EPO or spirulina
or together respectively, have signiﬁcantly decreased the
plasma NO levels, particularly in group (8), as compared to
the control diabetic rats in group (5).
Histological observations
The pancreatic sections of the normal control rats (non-dia-
betic rats group) stained with H&E showed normal architec-
ture of the pancreatic acini and islet of Langerhans. The
pancreatic acini consist of pyramidal cells containing basal
rounded nuclei. The apical region of each pyramidal cell con-
tains acidophilic granules (zymogenic granules), and the basal
part is basophilic. The islets of Langerhans are scattered
between the acini, they are rounded or oval in conﬁguration
and appeared faintly stained with H&E (Fig. 1). The pancre-
atic sections of the non-diabetic rats treated with EPO or spir-
ulina or co-treated with both agents (groups 2–4) have also
shown normal histological architecture (Figs. 2–4).
The sections of the pancreas of the alloxanized-diabetic rats
(group 5) showed necrotic areas, vacuolation in islet cells and
condensed ﬁbers around many blood capillaries (Fig. 5a and
b). In diabetic rats treated with EPO (group 6), the pancreatic
sections showed slight improvement in the minimization of the
vacuolated islets cells, reduction of ﬁbers around the blood
vessels (Fig. 6). Diabetic rats administered with spirulina
Figure 1 A photomicrograph of a pancreatic section of a normal
control rat showing normal architecture of acini (AC), islets of
Langerhans (IL), intercalated duct (ID) and pancreatic artery (A).
H&E, scale bar = 6.25 lm.
Figure 2 A photomicrograph of a pancreatic section of a non-
diabetic rat treated with EPO showing normal appearance of acini
(AC) and islet of Langerhans (IL). H&E, scale bar = 6.25 lm.
Figure 3 A photomicrograph of a pancreatic section of a non-
diabetic rat administered with spirulina showing normal appear-
ance of acini (AC) and islet of Langerhans (IL). H&E, scale
bar = 6.25 lm.
Figure 4 A photomicrograph of a pancreatic section of a rat
given EPO+ spirulina showing normal architecture of acini (AC),
islets of Langerhans (IL), intercalated duct (ID) and blood vessels
(BV). H&E, scale bar = 6.25 lm.
26 N.I. El-Desouki et al.demonstrated marked recovery of the pancreatic islets and aci-
nar cells (Fig. 7). Diabetic rats treated with EPO and spirulina
together showed an obvious recovery of pancreatic islet and
acinar cells to almost normal structure and normal distribution
of ﬁbers surrounding the blood vessels (Fig. 8).IHC observations
The pancreas of the normal control rats expressed normal
strong immunoreactivity to the insulin secreting b-cells
(Fig. 9). Similar normal results were expressed to b-cells in
Figure 5 (a and b) A photomicrograph of a pancreatic section of
alloxanized-diabetic rat showing: (a) necrotic areas (NA), vacuo-
lated cells (arrows) in islet of Langerhans (IL), abnormal acinar
cells (AC) and condensed ﬁbers (F) around a blood capillary (BC);
(b) vacuolated islet cells (IL), anomalous acinar cells (AC) and
markedly accumulated ﬁbers around pancreatic duct (ID) and
blood vessel (BV). H&E, scale bar = 6.25 lm.
Figure 6 A photomicrograph of a pancreatic section of a
diabetic rat treated with EPO showing the minimization of the
vacuolated cells and a reduction of necrotic areas in islet of
Langerhans (IL) and a recovery of most normal acinar cells (AC).
H&E, scale bar = 6.25 lm.
Figure 7 A photomicrograph of a pancreatic section of a
diabetic rat administered with spirulina showing marked improve-
ment of pancreatic islet (IL) and acinar cells (AC). H&E, scale
bar = 6.25 lm.
Improvement in beta-islets of Langerhans in alloxan-induced diabetic rats 27the non-diabetic rats treated with EPO, spirulina or both
together (data not shown). The alloxanized-diabetic rats
showed less expression of insulin secreting b-cells with clear
necrotic areas in islets of Langerhans (Fig. 10). The allox-
anized-diabetic rats given with the three treatment regimes
demonstrated an obvious increment in the expression of insu-
lin secreting b-cells. Animals treated with EPO showed a less
immunoreactivity (Fig. 11) in comparison to the diabetic rats
administered with spirulina (Fig. 12). The diabetic rats treated
with both EPO and spirulina together showed an obvious
recovery as indicated by the increase in the expression of the
insulin secreting b-cells (Fig. 13).Discussion
Diabetes is a pancreatic b-cell defect, manifested by b-cell
death and dysfunction. Alloxan is a diabetogenic agent which
is widely used in studies of experimental diabetes because it
selectively destroys the pancreatic b-cells of rats (El-Desouki,
2004) possibly through the mechanism of induction of free
radical species (Szkudelski, 2001) and oxidative stress that
Figure 8 A photomicrograph of a pancreatic section of a
diabetic rat given EPO and spirulina showing an obvious recovery
of pancreatic islet (IL) and acinar (AC) cells to almost normal
structure. See normal blood vessels (BV). H&E, scale
bar = 6.25 lm.
Figure 9 A photomicrograph of a pancreatic section of a control
rat showing strong expression of insulin secreting b-cells (arrow).
Anti-insulin immunostain, scale bar = 6.25 lm.
Figure 10 A photomicrograph of a pancreatic section of
alloxanized-diabetic rat demonstrating a decrease expression of
insulin secreting b-cells (arrows) and a clear necrotic area (NA) in
an islet. Anti-insulin immunostain, scale bar = 6.25 lm.
Figure 11 A photomicrograph of a pancreatic section of a
diabetic rat treated with EPO showing a limit increase in the
expression of insulin secreting b-cells in some islets (one arrow)
and more expression in other islet (double arrow). Anti-insulin
immunostain, scale bar = 6.25 lm.
28 N.I. El-Desouki et al.impaired insulin secretion in type 2 diabetes (Robertson, 2006).
In the recent study, the plasma glucose values were signiﬁ-
cantly increased and insulin levels were signiﬁcantly decreased
after induction of diabetes by alloxan in rats, and the treat-
ment of diabetic rats with EPO (40 u/kg) or/and spirulina
(2 g/kg/d) for 3 weeks successfully ameliorated the diabetic
complications by declined glucose levels and enhanced again
insulin levels reﬂecting a restoration of the pancreatic b-cells
activity. These results were in agreement with the reports that
have documented previously the effect of EPO on reduction
blood glucose levels in human and experimental animals
(Rasic-Milutinovic et al., 2008) and may result from anincrease in the erythrocyte counts and their consequent uptake
of glucose (Montel-Hagen et al., 2009).
EPO treatment has antiapoptotic, proliferative and angio-
genic effects on the pancreatic islets. It inhibits apoptosis in
b-cells during diabetes progression (Motoyama et al., 1995).
Fenjves et al. (2003) recorded that EPO treatment ameliorated
and reduced insulin levels to a great extent due to its effect
directly on pancreatic b-cells. Similar results were recorded
Figure 12 A photomicrograph of a pancreatic section of a
diabetic rat administered with spirulina seeing marked improve-
ment and an increase in the expression of insulin secreting b-cells
(arrow). Anti-insulin immunostain, scale bar = 6.25 lm.
Figure 13 A photomicrograph of a pancreatic section of a
diabetic rat given EPO and spirulina demonstrating a marked
recovery of normal strong expression of insulin secreting b-cells
(arrow). Anti-insulin immunostain, scale bar = 6.25 lm.
Improvement in beta-islets of Langerhans in alloxan-induced diabetic rats 29by Marzo et al. (2008). However, Brines and Cerami (2006)
demonstrated that the protective effect of EPO on the b-cells
under diabetes conditions occurs largely through the promo-
tion of b-cell growth and survival rather than through direct
effects on b-cell function.
The present results showed that the possible mechanism by
which spirulina brings about its antihyperglycemic action may
be through potentiation of the pancreatic secretion of insulin
from islet b-cells or due to enhancement of the blood glucose
transport to the peripheral tissue (Layam and Reddy 2006).
The biochemical results in the present work demonstrated
that the diabetic rats displayed a signiﬁcant increment in NO
levels while SOD and CAT were signiﬁcantly declined. Manystudies suggested that the hyperglycemia has been associated
with oxidative stress and increased levels of NO and reactive
oxygen species (ROS) that have been proposed to induce insu-
lin resistance (Chong et al., 2005). The author and his col-
leagues recorded that NO exerted a deleterious effect on ß-
cells through the inactivation of enzymes that are speciﬁcally
protective against oxidative stress damage. Oxidative stress
and NO pathways were related and seemed to modulate each
other, leading to b-cells destruction in diabetes. The excess of
NO production in the pancreas of diabetes involved an
increase activity of nitric oxide synthase (NOS), whose level
was higher in diabetic than in control tissue. The enhancement
of NOS activity in diabetic tissues was the result of the induc-
tion of the Ca2+-independent isoform. This agreed with
McDaniel et al. (1996) who stated that ß-cells, selectively
destroyed in diabetes, seem to express the inducible isoform
of NOS and to overproduce NO, which exerts deleterious
effects on their function.
Also, high amounts of ROS have been shown to play a role
in the development of diabetic complications as well as in a
number of other disease states. ROS generated during metabo-
lism can enter into reactions that, when uncontrolled, can
affect certain processes leading to clinical manifestations.
Oxidative stress induced by excessive production of superoxide
and an imbalance in antioxidant enzymes (SOD & CAT) has
been linked to the development of diabetic complications
(Kesavulu et al., 2000).
The current results recorded that the treatment of EPO or/
and spirulina to diabetic rats caused a signiﬁcant decrease of
the NO levels and increased in the antioxidant SOD and
CAT values. Many authors reported that EPO may reﬂect
another consideration for diabetic therapeutic strategies.
Protection by EPO in a number of cellular systems can block
apoptotic injury from a number of sources, such as reduced
or absent oxygen tension, cytotoxicity and free radical expo-
sure (Li et al., 2004, 2006). EPO treatment resulted in reduced
lipid peroxidation and enhanced SOD, CAT, and other
antioxidant activities. Moreover, EPO is a highly sialidated
glycoprotein. It has been reported that mucin, a typical sialic
acid containing high-molecular weight glycoprotein, is an
anti-oxidant and that sialic acid is crucial for this activity
(Ogasawara et al., 2007).
Concerning spirulina, many studies indicated the cyanobac-
terial proteins in spirulina are the molecules of high potency to
work as antioxidants by scavenging peroxyl, hydroxyl,
peroxynitrite, superoxide radicals, and as inhibitors of lipid
peroxidation (Bhat and Madyastha, 2001). Other studies sug-
gested that spirulina contains several active ingredients, nota-
bly phycocyanin and b-carotene that have potent antioxidant
and anti-inﬂammatory activities (Shih et al., 2009; Manconia
et al., 2009).
The histological and IHC observations conﬁrmed the bio-
chemical data in the current study. The results showed that
the diabetes caused changes in rat pancreatic tissue as islet vac-
uolization, degeneration and necrosis of b-cells, dilation of
intercalated duct and inﬁltration of inﬂammatory cells.
Moreover, the expression of insulin secreting cells (b-cells) by
using monoclonal anti insulin markedly demonstrated the
destruction and reduction of b-cells immunoreaction in dia-
betic rats. EPO or spirulina or co-treatment minimized and
improved the changes associated with pancreatic rat diabetes
and enhanced the expression of b-cells in the islets of
30 N.I. El-Desouki et al.Langerhans, more improved in spirulina than in EPO rat
groups, and the co-treatment of EPO and spirulina exerted
stronger anti-hyperglycemic effects than treatment with each
agent alone. Similar results have been reported by many
authors; Marchetti et al. (2010) demonstrated the reduction
of islet number and/or diminished beta-cell mass/volume in
the pancreas of type 2 diabetes and morphological changes
in several beta-cell organelles. Moreover, Patel et al. (2014)
showed a decrease counting analysis in the number of pancre-
atic b-cells immunostain of obese-hyperglycemic mice that
indicated the islets were losing the ability to secrete insulin efﬁ-
ciently (Deng et al., 2004).
EPO and spirulina have protective effects on pancreatic
b-cell functions and may due to their powerful antioxidant
properties. Supporting these ﬁndings was discussed above.
In conclusion, all the changes in the physiological parame-
ters, histopathological and the degeneration of pancreatic
b-cells immunoreactivity of alloxanized-diabetic rats were
improved by spirulina more than by EPO, and the co-treat-
ment of EPO and spirulina acts as hypoglycemic effect than
the treatment with each separately.References
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